Company news

Share this article:
Schering-Plough Corporation announced that it has received antitrust clearance from the Federal Trade Commission regarding its planned acquisition of Organon BioSciences from Akzo Nobel as announced March 12. Organon BioSciences is comprised mainly of Organon, the human pharmaceutical business, and Intervet, the animal health business. It also includes Nobilon, the human vaccine development unit, and Diosynth, the third- party manufacturing unit of Organon. Schering-Plough received approval from The European Commission on Oct. 11, and continues to expect the transaction to be completed by year-end 2007.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.